Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG). (Q44827042)
Jump to navigation
Jump to search
scientific article published in November 1990
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG). |
scientific article published in November 1990 |
Statements
1 reference
Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG). (English)
1 reference
E Hellström
1 reference
K H Robèrt
1 reference
J Samuelsson
1 reference
C Lindemalm
1 reference
G Grimfors
1 reference
E Kimby
1 reference
G Oberg
1 reference
I Winqvist
1 reference
R Billström
1 reference
J Carneskog
1 reference
1 November 1990
1 reference
1 reference